Ning Hui, Liu Ming, Wang Lina, Yang Yang, Song Nan, Xu Xiaoxiong, Ju Jin, Jiang Gening
Department of Thoracic Surgery, Shanghai Pulmonary Hospital affiliated Tongji University, Shanghai 200433, China.
Department of Thoracic Surgery, Tianjin Haihe Hospital, Tianjin 300350, China.
J Thorac Dis. 2017 Mar;9(3):796-801. doi: 10.21037/jtd.2017.03.13.
() gene was the major causative gene of lung cancer and also the specific treatment target. It is necessary to analyze the genotype and phenotype characters of patients.
We investigated 1,034 lung cancer patients in this study. The collected clinicopathological parameters included gender, age at diagnosis, smoking status, pathological TNM stage, tumor morphology and location, visceral pleural invasion as well as histological type.
Almost 50% participants had mutations. L858R in exon 21 was the most common type. Concomitant mutation, 19 del and L858R, were detected in 20 patients. Compared to patients with exon 19 del or L858R mutations solely, they were inclined to have small size adenocarcinomas which occurred in bilateral and invaded the visceral pleura. The tyrosine kinases inhibitors (TKIs)-resistant mutation, insertions in exon 20, was detected in 11 patients.
The summarized clinicopathological features will help clinicians to implement the feasible treatment plan.
（）基因是肺癌的主要致病基因，也是特定的治疗靶点。分析患者的基因型和表型特征很有必要。
本研究纳入了1034例肺癌患者。收集的临床病理参数包括性别、诊断时年龄、吸烟状况、病理TNM分期、肿瘤形态和位置、脏层胸膜侵犯以及组织学类型。
近50%的参与者存在 突变。外显子21中的L858R是最常见的类型。在20例患者中检测到伴随突变、19号外显子缺失和L858R。与仅存在外显子19缺失或L858R突变的患者相比，他们倾向于患有双侧发生、侵犯脏层胸膜的小腺癌。在11例患者中检测到酪氨酸激酶抑制剂（TKIs）耐药突变，即外显子20插入。
总结的临床病理特征将有助于临床医生实施可行的治疗方案。
